AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22743161
Drug: Persistent drug
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Persistent drug users (used illicit drugs other than marijuana and/or nonmedical prescription drugs every year during the first four years)
Trial: 22743161
Drug: Persistent drug
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Persistent drug users and infrequent marijuana users
Trial: 3022785
Drug: Interferon (topically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (topically applied in a gel)
Trial: 29953567
Drug: Positive control
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive control (commercially available denture adhesive cream)
Trial: 24141036
Drug: Risedronate 150
RxNorm normalized name: risedronate 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 150 mg orally every month
Trial: 21211262
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of high‐dose pirarubicin during perioperative period
Trial: 1653142
Drug: Sumatriptan (100-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (100-300 mg oral)
Trial: 1653142
Drug: Sumatriptan (4-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (4-8 mg subcutaneous)
Trial: 6136437
Drug: Long-acting vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting vaginal pessary containing 3.0 mg 15-methyl-PGF2(α) methyl ester
Trial: 6136437
Drug: Intraamniotic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraamniotic administration of 2.5 mg 15-methyl-PGF2(α)
Trial: 6136437
Drug: Long-acting vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting vaginal pessary complemented with intramuscular injections of 15-methyl-PGF2(α) (0.2-0.4 mg every third hour for up to 12 hours)
Trial: 6136437
Drug: Intraamniotic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraamniotic administration of 15-methyl-PGF2(α)
Trial: 30247950
Drug: Mistletoe extracts
RxNorm normalized name: MISTLETOE EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mistletoe extracts (Helixor A, Iscador M Spez) injected three times per week during 18 weeks of chemotherapy
Trial: 16968813
Drug: Both Pioglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Pioglitazone and Metformin
Trial: 15030987
Drug: 18 months
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 18 months combination therapy with interferon (3MU tiw) and ribavirin (1000-1200 mg/day)
Trial: 15030987
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months combination therapy with interferon and ribavirin
Trial: 9661572
Drug: i.v. fluconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. fluconazole 400 mg
Trial: 9661572
Drug: oral fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral fluconazole 400 mg
Trial: 4596632
Drug: Zinc sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulphate administered for six weeks
Trial: 31124381
Drug: Cholecalciferol tablet
RxNorm normalized name: Alendronate Sodium and Cholecalciferol Tablets
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol tablet 60,000 IU per week for 8 weeks
Trial: 28867602
Drug: Secnidazole 2
RxNorm normalized name: secnidazole 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secnidazole 2 g
Trial: 21557440
Drug: Neutral protamine
RxNorm normalized name: Neutral protamine hagedorn insulin
DrugBank: Neutral Protamine Hagedorn (NPH) insulin (DB18001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral protamine hagedorn insulin
Trial: 16687897
Drug: Initial resuscitation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial resuscitation, appropriate antimicrobial treatment, selection of optimal control methods, properties of fluid therapy, use of vasopressors and inotropic therapy, proper corticosteroid administration, use of recombinant human activated protein C, glucose control
Trial: 7961011
Drug: Total duration
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total duration of treatment < 55 days
Trial: 7961011
Drug: Dose rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose rate
Trial: 26683985
Drug: Parent education
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent education brochure plus a student curriculum on the four recommended vaccines
Trial: 19731862
Drug: Itraconazole (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (administered to group A)
Trial: 16353228
Drug: Sonographically guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonographically guided steroid injection (7 mg betamethasone and 0.5 ml of 1% lidocaine)
Trial: 16353228
Drug: Palpation-guided steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palpation-guided steroid injection (7 mg betamethasone and 0.5 ml of 1% lidocaine)
Trial: 10911415
Drug: 10 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 weeks of supervised physical therapy
Trial: 8864313
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg racemic ketoprofen
Trial: 8864313
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg racemic ketoprofen
Trial: 1551350
Drug: Alginic acid-antacid
RxNorm normalized name: Alginic Acid
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginic acid-antacid (extra-strength Gaviscon)
Trial: 1551350
Drug: Control antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control antacid (equal acid-neutralizing capacity)
Trial: 30584459
Drug: Polyphenol-rich herbal
RxNorm normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenol-rich herbal congee (D2 group, 1500 mg/day)
Trial: 30584459
Drug: Polyphenol-rich herbal
RxNorm normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenol-rich herbal congee (D1 group, 50 mg/day)
Trial: 27662495
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment for 10 minutes at GV 26, Ex-HN 3, bilateral LI 4, and ST 36
Trial: 15950847
Drug: Intravenous hydroxyethyl
RxNorm normalized name: Hydroxyethyl Cellulose
DrugBank: Hydroxyethyl cellulose (DB11602)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydroxyethyl starch (HES) 6% 200,000/0.5, 500 mL
Trial: 15950847
Drug: Electrolyte solution,
RxNorm normalized name: electrolyte solution,lactated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrolyte solution, 500 mL
Trial: 12390336
Drug: High-level TSH
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-level TSH suppression (0.4-0.6 mIU/ml)
Trial: 12390336
Drug: Low-level TSH
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level TSH suppression (< or = 0.01 mIU/ml)
Trial: 10563539
Drug: Regular paper-filtered
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular paper-filtered coffee (280 ml)
Trial: 10563539
Drug: Warm water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm water (280 ml)
Trial: 26012232
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic injected subcutaneous (GA)
Trial: 26012232
Drug: Saline subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline subcutaneous & deep (GC)
Trial: 19153001
Drug: Epirubicin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (80 mg in 50 ml of saline) intravesically within 24 h of TUR
Trial: 19153001
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment after TUR
Trial: 17578314
Drug: Ruyi Dingchuan
RxNorm normalized name: BENZALKONIUM CHLORIDE 0.148 g in 100 mL TOPICAL SPRAY [Jingchuang Chonggao Disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruyi Dingchuan Pill (RDP)
Trial: 11004346
Drug: Salivary estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salivary estriol (E3) test at or above 2.1 ng/mL
Trial: 11004346
Drug: Salivary E3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salivary E3 test at or above 1.4 ng/mL
Trial: 8988071
Drug: Ephedrine plus
RxNorm normalized name: EPHEDRINE HYDROCHLORIDE 12.5 mg / GUAIFENESIN 200 mg ORAL TABLET [Red Label Ephedrine Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine plus caffeine (20 mg ephedrine plus 200 mg caffeine three times a day)
Trial: 1730189
Drug: Cefotaxime 1
RxNorm normalized name: cefotaxime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 1 g every 8 hr
Trial: 1730189
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g every 12 hr
Trial: 6143505
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg sublingually, followed by 10 mg every 6 hours for a total of 24 hours)
Trial: 31460669
Drug: Concurrent opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent opioids with benzodiazepines or nonbenzodiazepine sedatives (BZD-S)
Trial: 30518044
Drug: NU-AGE diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NU-AGE diet group (dietary intervention for one year including 15 food groups and vitamin D supplement)
Trial: 22424012
Drug: Transendocardial injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TRANSENDOCARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transendocardial injection of autologous aldehyde dehydrogenase-bright (ALDH(br)) cells
Trial: 20142410
Drug: One course
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One course of adjuvant CVB chemotherapy for VASC- patients
Trial: 20142410
Drug: Two courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two courses of adjuvant CVB chemotherapy for VASC+ patients
Trial: 20142410
Drug: Adjuvant CVB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant CVB chemotherapy (both groups)
Trial: 19020146
Drug: Demand-only PCEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demand-only PCEA (5 mL bolus, 15 min lockout interval)
Trial: 19020146
Drug: PCEA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA with background infusion (5 mL/h, 5 mL bolus, 12 min lockout interval)
Trial: 19020146
Drug: PCEA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA with background infusion (10 mL/h, 5 mL bolus, 10 min lockout interval)
Trial: 7493430
Drug: Biosynthetic human
RxNorm normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic human growth hormone, subcutaneously, daily dose of 0.02-0.05 i.u./kg at bedtime
Trial: 31125576
Drug: Sorafenib-pravastatin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib-pravastatin combination (arm A)
Trial: 22794223
Drug: SAF as
RxNorm normalized name: SAF-GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAF as an adjunct after K3
Trial: 20700793
Drug: Topical nipradilol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nipradilol
Trial: 19203070
Drug: ACE‐inhibitor quinaprilat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE‐inhibitor quinaprilat 0.5 mg/h administered intravenously via infusion pump
Trial: 19203070
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard inotropic‐vasodilator therapy)
Trial: 11861525
Drug: PPARγ agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPARγ agonists (chronic treatment for 11 days)
Trial: 11861525
Drug: Rosiglitazone (14-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (14-day treatment)
Trial: 11861525
Drug: Metformin or
RxNorm normalized name: metformin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin or PPARα agonist (treatment)
Trial: 11861525
Drug: Severe insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Severe insulin resistance patients (dominant-negative PPARγ mutations)
Trial: 7488811
Drug: Budesonide (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (inhaled steroid)
Trial: 30280515
Drug: 0.1% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% sodium hyaluronate (SH) ophthalmic solution
Trial: 30280515
Drug: 0.2% sodium
RxNorm normalized name: Dextrose 5% and 0.2% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% sodium hyaluronate (SH) ophthalmic solution
Trial: 30280515
Drug: 0.3% sodium
RxNorm normalized name: Dextrose 5% and 0.3% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% sodium hyaluronate (SH) ophthalmic solution
Trial: 30280515
Drug: All sodium
RxNorm normalized name: Sodium Chloride 0.9% Intravenous Solution [KENDALL SODIUM CHLORIDE FLUSH SYRINGE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All sodium hyaluronate solutions
Trial: 30280515
Drug: All ophthalmic
RxNorm normalized name: All Clear Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All ophthalmic solutions
Trial: 14994114
Drug: 0.2 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 percent isosorbide dinitrate ointment
Trial: 12074178
Drug: Low-NaFeEDTA group
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-NaFeEDTA group (consuming fortified soy sauce, providing 5 mg Fe/day)
Trial: 12074178
Drug: High-NaFeEDTA group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-NaFeEDTA group (consuming fortified soy sauce, providing 20 mg Fe/day)
Trial: 9844789
Drug: Dihydrexidine (full
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrexidine (full D1 receptor agonist), single intravenous doses ranging from 2 mg to a maximum of 70 mg infused over 15 or 120 minutes
Trial: 9844789
Drug: Dihydrexidine (full
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrexidine (full D1 receptor agonist)
Trial: 7865640
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg twice daily for 5 days
Trial: 7865640
Drug: Dosing after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing after food
Trial: 2556456
Drug: Enalapril, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril, 80 mg/day
Trial: 4331769
Drug: Kethoxal 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kethoxal 2.5% cream
Trial: 25297637
Drug: PEG‐IFN‐SA (1.5 μg kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN‐SA (1.5 μg kg(‐1) s.c.)
Trial: 25297637
Drug: peginterferon‐α‐2a (180 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon‐α‐2a (180 μg s.c.)
Trial: 19289135
Drug: Treadmill-walking exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treadmill-walking exercise (twice weekly for 8 weeks)
Trial: 28561192
Drug: No cardiovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cardiovascular medication
Trial: 28561192
Drug: Peripherally acting
RxNorm normalized name: Peripherally acting antiobesity products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripherally acting medication
Trial: 28561192
Drug: Centrally acting
RxNorm normalized name: Other centrally acting agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centrally acting medication
Trial: 25565587
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care along with receipt of twice‐daily supportive SMS text messages during the second and third week of the study
Trial: 8921775
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E within the drug group
Trial: 8921775
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C within the drug group
Trial: 1715740
Drug: FK506 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK506 with low-dose steroids
Trial: 385873
Drug: 1,200 mg
RxNorm normalized name: lecithin 1,200 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200 mg oxaprozin given as a single daily dose
Trial: 385873
Drug: 3,900 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,900 mg ASA given in 4 equally divided doses
Trial: 24381967
Drug: 20 mg/d
RxNorm normalized name: Valtoco, 20 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/d of memantine
Trial: 24381967
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of alpha tocopherol and memantine
Trial: 20024737
Drug: Discussion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discussion of oral health with HIV primary care providers
Trial: 20024737
Drug: Illicit drug
RxNorm normalized name: Illicium difengpi bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Illicit drug use among men
Trial: 16400234
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with aluminium hydroxide adsorbed house dust mite allergoid
Trial: 29688838
Drug: Intense Pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense Pulsed Light (IPL) treatment applied directly on the eyelids, with three treatments at 4-week intervals.
Trial: 29688838
Drug: Sham IPL
RxNorm normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham IPL treatment (control group).
Trial: 28556458
Drug: Behaviour change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour change intervention (provision of hardware: bin for solid waste, 4 l flushing bucket, 70 l water reservoir; behaviour change communication: compound meetings, interpersonal household sessions, signs depicting rules for toilet use)
Trial: 20865582
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion at 0.5 mcg/kg/hour during operation
Trial: 19045962
Drug: Problem-solving treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving treatment for primary care (PST-PC)
Trial: 3074776
Drug: Subcutaneous corrugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous corrugated drains
Trial: 31796304
Drug: Remifentanil 1μg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1μg.kg‐1 bolus + 0.15μg.kg‐1.min‐1 infusion (stopped after skin incision)
Trial: 19087756
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (10 sessions)
Trial: 19087756
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy and Control
Trial: 11762564
Drug: Midazolam oral
RxNorm normalized name: midazolam Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam oral syrup administration
Trial: 11762564
Drug: Midazolam intravenous
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam intravenous administration
Trial: 11762564
Drug: Midazolam bioavailability
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam bioavailability
Trial: 11762564
Drug: Initial oral
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial oral dose of midazolam
Trial: 8149521
Drug: Hirudin (0.05,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirudin (0.05, 0.10, 0.20, or 0.30 mg.kg‐1.h‐1 infusion)
Trial: 8149521
Drug: Heparin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (target aPTT of 65 to 90 or 90 to 110 seconds)
Trial: 29474588
Drug: No reperfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No reperfusion therapy (Control)